Halozyme Therapeutics (HALO) News Today $55.94 +1.14 (+2.08%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period H.C. Wainwright Sticks to Their Buy Rating for Summit Therapeutics (SMMT)January 21 at 8:44 PM | markets.businessinsider.comAMI Asset Management Corp Has $1.79 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)AMI Asset Management Corp trimmed its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 23.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 37,460 shares of the biopharmaceuticaJanuary 21 at 8:28 AM | marketbeat.comSugar Maple Asset Management LLC Invests $373,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Sugar Maple Asset Management LLC acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 7,800 shares of the biopharmaceutJanuary 21 at 6:48 AM | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Short Interest UpdateJanuary 21 at 3:19 AM | americanbankingnews.comLeerink Partners Keeps Their Buy Rating on Oruka Therapeutics (ORKA)January 20 at 6:55 AM | markets.businessinsider.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Sees Large Growth in Short InterestHalozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 9,500,000 shares, an increase of 8.1% from the December 15th total of 8,790,000 shares. Based on an average daily trading volume, of 1,670,000 shares, the short-interest ratio is presently 5.7 days. Approximately 7.6% of the shares of the stock are short sold.January 19 at 6:46 PM | marketbeat.comEmpirical Asset Management LLC Purchases Shares of 22,810 Halozyme Therapeutics, Inc. (NASDAQ:HALO)Empirical Asset Management LLC acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 22,810 shares of the biopharJanuary 19 at 3:53 AM | marketbeat.comBernzott Capital Advisors Invests $4.49 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Bernzott Capital Advisors bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 93,985 shares of the biopharmacJanuary 17, 2025 | marketbeat.comOutlook Wealth Advisors LLC Invests $355,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Outlook Wealth Advisors LLC purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 7,428 shares of the biopharmJanuary 17, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for HALO FY2025 Earnings?January 16, 2025 | americanbankingnews.comEquities Analysts Set Expectations for HALO Q1 EarningsJanuary 16, 2025 | americanbankingnews.comVera Therapeutics Getting Closer To Key Technical BenchmarkJanuary 15, 2025 | msn.comFY2025 Earnings Forecast for HALO Issued By Leerink PartnrsHalozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Equities research analysts at Leerink Partnrs reduced their FY2025 earnings per share (EPS) estimates for Halozyme Therapeutics in a research note issued to investors on Sunday, January 12th. Leerink Partnrs analyst D. Risinger now anticipJanuary 15, 2025 | marketbeat.comBalanced Outlook on Halozyme Amid Litigation and Strategic Uncertainty Warrants Hold RatingJanuary 15, 2025 | markets.businessinsider.comHalozyme: Undervalued Growth Potential Amidst Strong Core Business and Future OpportunitiesJanuary 14, 2025 | markets.businessinsider.comQ1 Earnings Estimate for HALO Issued By Leerink PartnrsHalozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Halozyme Therapeutics in a research report issued to clients and investors on Sunday, January 12th. Leerink Partnrs analyst D. Risinger expecJanuary 14, 2025 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Price Target Lowered to $57.00 at Wells Fargo & CompanyJanuary 14, 2025 | americanbankingnews.comHalozyme Therapeutics (NASDAQ:HALO) Price Target Cut to $57.00 by Analysts at Wells Fargo & CompanyWells Fargo & Company decreased their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research note on Monday.January 13, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Halozyme (HALO) and SAGE Therapeutics (SAGE)January 13, 2025 | markets.businessinsider.comHalozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $70.00 at HC WainwrightJanuary 13, 2025 | americanbankingnews.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) have been assigned an average rating of "Moderate Buy" from the ten analysts that are presently covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and six havJanuary 13, 2025 | marketbeat.comHalozyme price target lowered to $57 from $62 at Wells FargoJanuary 12, 2025 | markets.businessinsider.comHalozyme Therapeutics (NASDAQ:HALO) Given New $53.00 Price Target at Piper SandlerJanuary 12, 2025 | americanbankingnews.comWhat is Zacks Research's Estimate for HALO Q3 Earnings?January 12, 2025 | americanbankingnews.comCautious Outlook on Halozyme Amid Patent Expiration and Partnership ChallengesJanuary 11, 2025 | markets.businessinsider.comHalozyme price target raised to $53 from $52 at Piper SandlerJanuary 10, 2025 | markets.businessinsider.comHalozyme price target raised to $70 from $68 at H.C. WainwrightJanuary 10, 2025 | markets.businessinsider.comPiper Sandler Issues Positive Forecast for Halozyme Therapeutics (NASDAQ:HALO) Stock PricePiper Sandler boosted their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research report on Friday.January 10, 2025 | marketbeat.comHC Wainwright Issues Positive Forecast for Halozyme Therapeutics (NASDAQ:HALO) Stock PriceHC Wainwright increased their target price on Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a "buy" rating in a research report on Friday.January 10, 2025 | marketbeat.comZacks Research Issues Positive Outlook for HALO EarningsHalozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Analysts at Zacks Research lifted their Q3 2025 earnings per share (EPS) estimates for shares of Halozyme Therapeutics in a report issued on Tuesday, January 7th. Zacks Research analyst R. Department now anticipates that the biopharmaceutiJanuary 10, 2025 | marketbeat.comTD Cowen Keeps Their Buy Rating on Halozyme (HALO)January 9, 2025 | markets.businessinsider.comZacks Research Issues Optimistic Forecast for HALO EarningsHalozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Research analysts at Zacks Research boosted their Q1 2025 EPS estimates for shares of Halozyme Therapeutics in a research note issued on Tuesday, January 7th. Zacks Research analyst R. Department now anticipates that the biopharmaceuticalJanuary 9, 2025 | marketbeat.comFirst Hawaiian Bank Purchases 20,700 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)First Hawaiian Bank boosted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 56.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 57,550 shares of the biopharmaceutical company's stock aJanuary 9, 2025 | marketbeat.comSpringWorks Therapeutics Trying To Close In On Key Technical MeasureJanuary 9, 2025 | msn.comHalozyme’s Strategic Growth and Financial Strength Boosts Buy RatingJanuary 9, 2025 | markets.businessinsider.comHalozyme Preliminary 2024 Estimated Ranges Consistent With Guidance; Raises FY25 GuidanceJanuary 9, 2025 | markets.businessinsider.comHalozyme Therapeutics (NASDAQ:HALO) Shares Gap Up - Still a Buy?Halozyme Therapeutics (NASDAQ:HALO) Shares Gap Up - Here's WhyJanuary 8, 2025 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Updates FY 2025 Earnings GuidanceHalozyme Therapeutics (NASDAQ:HALO) updated its FY 2025 earnings guidance. The company provided EPS guidance of 4.950-5.350 for the period, compared to the consensus estimate of 4.690. The company also issued revenue guidance of $1.2 billionillion-$1.2 billionillion, compared to the consensus estimate of $1.2 billionillion.January 8, 2025 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Updates FY 2024 Earnings GuidanceHalozyme Therapeutics (NASDAQ:HALO) updated its FY 2024 earnings guidance. The company provided EPS guidance of 4.000-4.200 for the period, compared to the consensus estimate of 4.140. The company also issued revenue guidance of $970.0 millionillion-$1.0 billionillion, compared to the consensus estimate of $1.0 billionillion.January 8, 2025 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Releases FY25 Earnings GuidanceHalozyme Therapeutics (NASDAQ:HALO) updated its FY25 earnings guidance. The company provided EPS guidance of $4.95-$5.35 for the period, compared to the consensus estimate of $4.83. The company also issued revenue guidance of $1.150-$1.225 billionillion, compared to the consensus estimate of $1.16 billionillion.January 8, 2025 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Releases FY24 Earnings GuidanceHalozyme Therapeutics (NASDAQ:HALO) updated its FY24 earnings guidance. The company provided EPS guidance of $4.00-$4.20 for the period, compared to the consensus estimate of $4.14. The company also issued revenue guidance of $970-$1.02 billionillion, compared to the consensus estimate of $1.00 billionillion.January 8, 2025 | marketbeat.comHalozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial GuidanceJanuary 8, 2025 | prnewswire.comJeffrey William Henderson Sells 10,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) StockJanuary 8, 2025 | insidertrades.comInsider Sell: Jeffrey Henderson Sells 10,000 Shares of Halozyme Therapeutics Inc (HALO)January 7, 2025 | gurufocus.comFDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo (Dec. 27)January 7, 2025 | msn.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells $500,100.00 in StockHalozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now directly owns 43,611 shares in the company, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.January 7, 2025 | marketbeat.comZacks.com featured highlights include Leidos, Amazon.com, Halozyme Therapeutics and BioMarin PharmaceuticalJanuary 7, 2025 | finance.yahoo.comHalozyme Therapeutics Inc (HALO) Announces Investor Conference Call for 2025 Financial GuidanceJanuary 6, 2025 | gurufocus.comHalozyme to Host Investor Conference Call to Provide Updated 2025 Financial GuidanceJanuary 6, 2025 | prnewswire.comHalozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025January 3, 2025 | seekingalpha.com Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address HALO Media Mentions By Week HALO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HALO News Sentiment▼0.690.63▲Average Medical News Sentiment HALO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HALO Articles This Week▼209▲HALO Articles Average Week Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BIIB News Today UTHR News Today NBIX News Today INCY News Today BMRN News Today EXEL News Today EXAS News Today RGEN News Today MDGL News Today IONS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HALO) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HALO Stock Alerts